Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of EBITDA data on file, last reported at $37.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 33.7% year-over-year to $37.3 million; the trailing twelve-month figure through Mar 2026 stood at $189.5 million (down 2.83% YoY), and the FY2025 full-year result was $208.5 million, up 9.25% from the prior year.
• EBITDA retreated to $37.3 million in Q1 2026, from $38.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $65.5 million in Q3 2025 to a low of $11.9 million in Q3 2022.
• A 5-year average of $44.0 million and a median of $46.9 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 442.05% in 2023 and tumbled 54.47% in 2024, its largest moves.
• Tracing HRMY's EBITDA over 5 years: stood at $47.6 million in 2022, then decreased by 15.58% to $40.2 million in 2023, then surged by 38.64% to $55.7 million in 2024, then plunged by 30.81% to $38.6 million in 2025, then decreased by 3.28% to $37.3 million in 2026.
• Business Quant data shows HRMY's EBITDA at $37.3 million in Q1 2026, $38.6 million in Q4 2025, and $65.5 million in Q3 2025.